273 related articles for article (PubMed ID: 17156104)
1. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Scott R; Wu M; Sanchez M; Stein P
Int J Clin Pract; 2007 Jan; 61(1):171-80. PubMed ID: 17156104
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
4. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
Mohan V; Yang W; Son HY; Xu L; Noble L; Langdon RB; Amatruda JM; Stein PP; Kaufman KD
Diabetes Res Clin Pract; 2009 Jan; 83(1):106-16. PubMed ID: 19097665
[TBL] [Abstract][Full Text] [Related]
6. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Raz I; Hanefeld M; Xu L; Caria C; Williams-Herman D; Khatami H;
Diabetologia; 2006 Nov; 49(11):2564-71. PubMed ID: 17001471
[TBL] [Abstract][Full Text] [Related]
12. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study.
Hsieh SH; Lin JD; Cheng HY; Ho C; Liou MJ
Clin Ther; 2006 Sep; 28(9):1318-26. PubMed ID: 17062305
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
[TBL] [Abstract][Full Text] [Related]
15. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
Mistry GC; Maes AL; Lasseter KC; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
J Clin Pharmacol; 2008 May; 48(5):592-8. PubMed ID: 18353996
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
[TBL] [Abstract][Full Text] [Related]
17. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Perusicová J
Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
Seck T; Nauck M; Sheng D; Sunga S; Davies MJ; Stein PP; Kaufman KD; Amatruda JM;
Int J Clin Pract; 2010 Apr; 64(5):562-76. PubMed ID: 20456211
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Chan JC; Scott R; Arjona Ferreira JC; Sheng D; Gonzalez E; Davies MJ; Stein PP; Kaufman KD; Amatruda JM; Williams-Herman D
Diabetes Obes Metab; 2008 Jul; 10(7):545-55. PubMed ID: 18518892
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Miller S; St Onge EL
Ann Pharmacother; 2006; 40(7-8):1336-43. PubMed ID: 16868220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]